In C difficile infection, adding IV bezlotoxumab to standard antibiotics reduced recurrence at 12 weeks

Ann Intern Med. 2017 May 16;166(10):JC53. doi: 10.7326/ACPJC-2017-166-10-053.
No abstract available

Publication types

  • Comment

MeSH terms

  • Anti-Bacterial Agents*
  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Broadly Neutralizing Antibodies
  • Clostridioides difficile / immunology*
  • Clostridium Infections
  • Enterocolitis, Pseudomembranous
  • Humans
  • Recurrence

Substances

  • Anti-Bacterial Agents
  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Broadly Neutralizing Antibodies
  • bezlotoxumab